Biosyngen’s liver cancer therapy receives fast track designation
The US Food and Drug Administration (FDA) has granted fast track designation (FTD) to Biosyngen's T cell therapy BST02 for liver cancer.
The US Food and Drug Administration (FDA) has granted fast track designation (FTD) to Biosyngen's T cell therapy BST02 for liver cancer.
What's Your Reaction?
